Firocoxib 227 Mg Chewable

Verify with FDA CVM →

999 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
999
Total Reports
166
Deaths Reported
1660.0%
Death Rate

Active Ingredients

Firocoxib 227 Mg Chewable

Administration Routes

OralUnknownTopical

Species Affected

Dog 832
Unknown 138
Horse 17
Cat 8
Human 4

Most Affected Breeds

Retriever - Labrador 174
Unknown 148
Crossbred Canine/dog 81
Dog (other) 70
Shepherd Dog - German 61
Retriever - Golden 53
Dog (unknown) 46
Boxer (German Boxer) 45
Rottweiler 27
Mastiff 19

Most Reported Reactions

Vomiting 294
Other abnormal test result NOS 244
Lethargy (see also Central nervous system depression in 'Neurological') 146
Elevated blood urea nitrogen (BUN) 145
Elevated creatinine 117
Elevated serum alkaline phosphatase (SAP) 92
Death 90
Anorexia 83
Diarrhoea 78
Elevated alanine aminotransferase (ALT) 74
Death by euthanasia 73
Not eating 62

Outcome Breakdown

Outcome Unknown
423 (49.1%)
Recovered/Normal
162 (18.8%)
Ongoing
105 (12.2%)
Died
94 (10.9%)
Euthanized
72 (8.4%)
Recovered with Sequela
6 (0.7%)

Data Summary

Metric Value
Total adverse event reports 999
Reports involving death 166
Case-fatality rate (reported events) 1660.0%
Distinct species in reports 5
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Firocoxib 227 Mg Chewable Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 999 adverse event reports referencing Firocoxib 227 Mg Chewable, including 166 reports in which the animal died — a 1660.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Firocoxib 227 Mg Chewable. Reported administration routes include Oral, Unknown, Topical. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Firocoxib 227 Mg Chewable reports are Dog (832 reports), Unknown (138 reports), Horse (17 reports), with Dog accounting for the largest share. Within those species, Retriever - Labrador (174), Unknown (148), Crossbred Canine/dog (81) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Firocoxib 227 Mg Chewable are Vomiting (294), Other abnormal test result NOS (244), Lethargy (see also Central nervous system depression in 'Neurological') (146), Elevated blood urea nitrogen (BUN) (145). Of the 862 reports with a coded outcome, Outcome Unknown is the leading category at 49.1%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Firocoxib 227 Mg Chewable.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial